#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA5215271	F	Agonist activity at human GLP-1R expressed in HEK293 cells incubated for 30 mins and assessed as increase in cAMP accumulation measured by HTRF assay	Homo sapiens	18	ALA5214890	cell-based format	Scientific Literature
2.	ALA5215272	F	Agonist activity at human GLP-1R expressed in HEK293 cells incubated for 30 mins and assessed as increase in cAMP accumulation measured by HTRF assay relative to control	Homo sapiens	18	ALA5214890	cell-based format	Scientific Literature
3.	ALA5215273	F	Agonist activity at human GCGR expressed in HEK293 cells incubated for 30 mins and assessed as increase in cAMP accumulation measured by HTRF assay	Homo sapiens	18	ALA5214890	cell-based format	Scientific Literature
4.	ALA5215274	F	Agonist activity at human GCGR expressed in HEK293 cells incubated for 30 mins and assessed as increase in cAMP accumulation measured by HTRF assay relative to control	Homo sapiens	18	ALA5214890	cell-based format	Scientific Literature
5.	ALA5215275	F	In vivo agonist activity at GLP-1R in C57BL/6J DIO mouse at 10 nmol/kg, ip administered at -30 mins in presence of GLP1-R antagonist Jant-4 administered at 1 umol/kg, ip at -60 mins and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
6.	ALA5215276	F	In vivo agonist activity at GCGR in streptozotocin induced diabetic mouse model of C57BL/6J at 10 nmol/kg, ip administered at 0 mins in presence of GCGR antagonist LY240902 administered at 1 umol/kg, ip at -15 mins and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
7.	ALA5215277	F	Antidiabetic activity in DIO mouse assessed as reduction in blood glucose at 10 nmol/kg, ip pretreated with compound and followed by glucose challenge and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
8.	ALA5215280	F	Antidiabetic activity in DIO mouse assessed as reduction in plasma insulin level at 10 nmol/kg, ip pretreated with compound and followed by glucose challenge and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
9.	ALA5215281	F	Antidiabetic activity in db/db mouse assessed as reduction in blood glucose at 10 nmol/kg, ip pretreated with compound and followed by glucose challenge and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
10.	ALA5215284	F	Antidiabetic activity in db/db mouse assessed as reduction in plasma insulin level at 10 nmol/kg, ip pretreated with compound and followed by glucose challenge and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
11.	ALA5215287	F	Antidiabetic activity in overnight fasted male C57BL/6J mouse at 10 nmol/kg, ip administered at -30 mins in presence of GLP1-R antagonist Jant-4 administered at 1 umol/kg, ip at -60 mins and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
12.	ALA5215288	F	Antidiabetic activity in overnight fasted male C57BL/6J mouse at 10 nmol/kg, ip administered at -30 mins and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
13.	ALA5215289	F	Antidiabetic activity in 2 hrs fasted male C57BL/6J mouse at 10 to 30 nmol/kg, ip administered at 0 mins in presence of GLP1-R antagonist Jant-4 administered at 1 umol/kg, ip at -60 mins and somatostatin at 10 mg/kg, sc administered at -30 mins and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
14.	ALA5215290	F	Antidiabetic activity in 2 hrs fasted male C57BL/6J mouse at 10 to 30 nmol/kg, ip administered at 0 mins in presence of somatostatin at 10 mg/kg, sc administered at -30 mins and measured by oral glucose tolerance test	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
15.	ALA5215291	F	Antidiabetic activity in male DIO mouse assessed as reduction in acute food intake at 10 nmol/kg, sc measured at 0 to 2 hrs post administration	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
16.	ALA5215295	F	Antidiabetic activity in male DIO mouse assessed as reduction in acute food intake at 10 nmol/kg, sc measured at 24 hrs post administration	Mus musculus	1	ALA5214890	organism-based format	Scientific Literature
17.	ALA5215296	F	Antidiabetic activity in overnight fasted male C57BL/6J mouse assessed as reduction in acute food intake at 30 nmol/kg, sc administered at -0.5 hrs in presence of GLP1-R antagonist Jant-4 administered at 1 umol/kg, sc at -1 hr	Mus musculus	3	ALA5214890	organism-based format	Scientific Literature
18.	ALA5215297	F	Antidiabetic activity in overnight fasted male C57BL/6J mouse assessed as reduction in acute food intake at 30 nmol/kg, sc administered at -0.5 hrs	Mus musculus	3	ALA5214890	organism-based format	Scientific Literature
19.	ALA5215298	F	Antidiabetic activity in overnight fasted male Sprague-Dawley rat assessed as reduction in food intake at 10 nmol/kg, ip	Rattus norvegicus	1	ALA5214890	organism-based format	Scientific Literature
20.	ALA5215299	F	Antidiabetic activity in overnight fasted male Sprague-Dawley rat assessed as reduction in food intake at 100 nmol/kg, ip	Rattus norvegicus	1	ALA5214890	organism-based format	Scientific Literature